Get a Deep Insight into the Inflammatory Bowel Diseases: World Market Report 2009-2024

NEW YORK--(Business Wire)--
Reportlinker.com announces that a new market research report is available in its
catalogue.

Inflammatory Bowel Diseases: World Market Report 2009-2024

http://www.reportlinker.com/p0109865/Inflammatory-Bowel-Diseases-World-Market-Report-2009-2024.html

This brand new in-depth market analysis examines the current and future
prospects of the inflammatory bowel diseases (IBD) market. The world market for
intestinal anti-inflammatories was worth over $2400 million in 2008, and had
grown at 9% over the previous year. The value of other types of drugs used to
treat IBD, including immunosuppressants and monoclonal antibodies, approached
$12000m. It is predicted the market for intestinal anti-inflammatories and IBD
drugs to continue expanding, based on rising disease rates and evolving
diagnostic methods. Currently, IBD is under-diagnosed, especially in developing
countries. As governments and health services address chronic illnesses like
IBD, this market will expand into previously untreated regions. Continuing
studies and surveys indicate that IBD is spreading globally, and has an
especially high prevalence rate in India. In addition, the Latin American
countries experienced 14% sales growth last year, and are set to account for an
increasingly large share of the world market in years to come.

This report - Inflammatory Bowel Diseases: World Market 2009-2024 - discusses
and analyses the major drug categories used in the treatment of IBD. This report
forecasts the top brand-name and generic drugs used for IBD, including
monoclonal antibody therapies. How much of an impact will monoclonal antibodies
have on sales of other IBD-related therapies, for example? You should know and
ths report will tell you.

This report also analyses the major markets worldwide, discussing the principal
national markets in detail, in addition to the world market. Through this
report, you will discover how the leading markets will perform in the future,
and how the relative values of each region will change over time. The US was the
largest market in 2008, but will it retain its leading market share until 2024?
How will the European market share compare with the Asian market share in 2014,
2019 and 2024?

Drug types analysed and forecasted in this report - Inflammatory Bowel Diseases:
World Market 2009-2024 - include:

• Aminosalicylate acid / 5-ASA

• Corticosteroids

• Immunomodulators

• Antibiotics

• Biologic therapies

• Monoclonal antibodies.

• Includes unique primary material unavailable elsewhere

This report covers disease and therapy distinctions between the two major types
of IBD: Crohn`s disease and ulcerative colitis. It discusses these diseases and
addresses aetiological theories that impact upon treatment. We provide the
information you need to assess the future of those diseases and of the relevant
markets. Sources consulted include industrial databases, commercial information,
published economic research and market-specific interviews with experts in the
IBD field. The result is a comprehensive market- and industry-based report with
detailed analyses and informed opinion that you will not find anywhere else.

In particular, Inflammatory Bowel Diseases: The World Market 2009-2024 focuses
on the following essential aspects of that market:

• Forecast of the overall world IBD market from 2009 to 2024

• Forecasts of the current leading drugs` sales from 2009 to 2024

• Assessments of pipeline developments

• Analyses of short- and long-term drivers in the market

• Analyses of how disease theories impact upon treatment procedures

• Sales forecasts for the leading regional markets from 2009 to 2024, including
discussions of specific country markets

• Discussion of the importance of generics in the IBD market

• Discussion of why the market contains so many types of drugs, and what that
means for future developments

• Assessments of opportunities and threats in the IBD market worldwide

• Analyses of the impact monoclonal antibodies will have on the IBD market,
present and future.

Why you should buy this report:

• To receive a comprehensive assessment of the complex IBD market, including the
various types of therapies

• To receive a comprehensive analysis of the sales prospects for existing and
new IBD drugs from 2009 to 2024

• To discover which types of therapies are most likely to succeed over the
short- and long-term, and why each will succeed

• For a thorough assessment of the current and future market at global and
regional levels

• To find out where the market is heading, both technologically and commercially

• For a logical analysis of the multifaceted treatment options for IBD,
including market drivers and restraints.

The global IBD market is highly complex, with multiple drugs being used
simultaneously and/or sequentially for therapy. The market can therefore accept
a large number of drugs, but the market is already fairly saturated, with
several similar drugs on the market. What does such saturation mean for the
futures of existing drugs? What does this mean for the pipeline? If, as the
author's report interviewees say, IBD current drugs are less efficacious than
they could be, what then are the promising future treatments that could fill
therapeutic gaps? This report covers those important matters, amongst others.

As inflammatory bowel disease rates continue to rise, as too public awareness
spreads and more-thorough diagnostic procedures expand the number of patients,
the demand for IBD drugs will increase. What drugs and which companies will meet
these therapeutic needs successfully in the future? Can new and future therapies
compete successfully with established treatments?

This report answers those and other important questions, to enable you to take
advantage of this expanding market.

Table of Contents

1 Executive Summary

1.1 Inflammatory Bowel Diseases (IBD) Market Trajectory

1.1.1 Prediction for the IBD Market

1.1.2 Prevalence Rates Rising Worldwide

1.2 Aims, Scope and Format of the Report

1.2.1 Chapter Outline

1.3 Complexities of the IBD Market: Assessing Multiple Drug Categories

1.4 Research Methods

2 What Is Inflammatory Bowel Disease?

2.1 Definition and Diagnosis

2.2 Signs, Symptoms and Secondary Conditions

2.2.1 Bleeding Ulcers, Fistulae, Bowel Perforations, Toxic Megacolon

2.2.2 Pyoderma Gangrenosum

2.2.3 Primary Sclerosing Cholangitis

2.2.4 Malnutrition, Poor Nutrient Absorption and Stunting

2.3 Ulcerative Colitis

2.4 Crohn's Disease

2.5 Indeterminate Colitis: Distinguishing Crohn's Disease from Ulcerative
Colitis

2.6 Causes / Aetiology of Inflammatory Bowel Disease

2.7 Prevalence

2.8 Socioeconomic Costs

2.8.1 The Individual Cost of IBD

3 Autoimmune Disorders

3.1 Brief Overview of the Immune System

3.2 What are Autoimmune Diseases / Disorders?

3.3 What Causes Autoimmune Disorders?

3.4 Why are Autoimmune Diseases Spreading in Developed Countries, but Not in
Developing Countries?

3.4.1 The Hygiene Hypothesis

3.5 What Inflammation is and Why Inflammation is Dangerous

3.5.1 What is Inflamed in Inflammatory Bowel Disease?

3.5.2 The Costs and Consequences of Non-Treatment

4 Treatments for Inflammatory Bowel Diseases

4.1 The Goals of IBD Treatment

4.1.1 Producing Remission

4.1.2 Maintaining Remission

4.2 Drug Categories and their Mechanisms of Action

4.2.1 Aminosalicylates / 5-ASA / Mesalazine / Mesalamine

4.2.2 Corticosteroids

4.2.3 Immunomodulators

4.2.4 Antibiotics

4.2.5 Biologic Therapies / Monoclonal Antibodies

4.3 Surgical Treatments

4.3.1 Surgery for Ulcerative Colitis

4.3.2 Surgery for Crohn's Disease

4.4 The Leading Alternative Treatments: Hygiene Theory, Helminthic Therapy and
Faecal Bacteriotherapy

4.4.1 Helminthic Therapy

4.4.2 Faecal / Fecal Bacteriotherapy / Human Probiotic Infusions (HPI)

4.4.3 Smoking

5 World IBD Market: Market Projection, Top Drug Projections

5.1 World Inflammatory Bowel Diseases Market, 2009-2024

5.1.1 The 5 Types of IBD Drugs

5.1.2 Other Drugs Cross-Indicated for IBD: Accounting for Monoclonal Antibodies

5.2 Lialda: Easier to Use, Growing in Significance

5.2.1 Unique Selling Point: Lialda is Lactose-Free

5.2.2 Lialda's Downside

5.3 Asacol

5.4 Entocort

5.4.1 Steroid Side Effects and Entocort EC

5.5 Pentasa

5.5.1 Excellent Safety Profile Assisting Pentasa's Sales

5.6 Salofalk

5.6.1 Salofalk Once-Daily

5.6.2 Salofalk and China Medical Sales Agreement

5.7 Budenofalk: 22% growth last year

5.7.1 Sales to be Boosted by New Sales Deal with Salix

5.8 Colazal: Losing Ground

5.9 Monoclonal Antibodies Forecasts

5.10 Remicade

5.10.1 Label Expansion Assisting Remicade's Sales

5.11 Humira

5.11.1 Label Expansion Behind Humira's Growth

5.11.2 Registered for Crohn's in US and EU; In Phase III for Crohn's in Japan

5.12 Cimzia

5.12.1 Challenged by the Committee for Medicinal Products for Human Use

5.13 Tysabri

5.13.1 Still Under Scrutiny for Liver Toxicity

6 Crucial Pipeline Developments: New Drug Targets, Innovative Delivery
Technologies, and Cutting-Edge Treatments

6.1 Traficet-EN

6.2 Alicaforsen: Approved for Pouchitis, Cancelled for Crohn's, Under Assessment
for UC

6.3 Rifaxamin

6.4 Myoconda: Is this the Cure for IBD?

6.5 Bupropion (Wellbutrin)

6.6 Abatacept (Orencia)

6.7 Polyketals: Technology to Deliver Drugs to Internal Inflammation

6.8 Extracorporeal Photopheresis (Light Therapy Outside of the Body): Uvadex
(Methoxsalen)

6.9 A New Monoclonal Antibody Indicated for Crohn's Disease: Ustekinumab
(Stelara)

6.10 Interleukins: Promising New Drug Targets (with a Table of Pipeline
Interleukin Drugs)

6.11 Stem Cells: Prochymal by Osiris Therapeutics

7 Leading Companies

7.1 Procter & Gamble: 27% of the IBD Market

7.2 Ferring: Drug Originator and Innovator, but Limited Late-stage Pipeline

7.3 Shire

7.3.1 Lialda's Success and its Potential

7.3.2 Shire's Share of Pentasa

7.4 Dr. Falk

7.5 Prometheus Laboratories: Significance through IBD Drugs and Tests

7.5.1 Prometheus's Diagnostic and Genetic Analysis Tests: Frontiers of IBD
Treatment

7.5.2 Serology Retrospective Results

7.5.3 Prometheus and Monoclonal Antibodies

7.6 Salix: Losing Colazal, Gaining US License to Budenofalk

7.7 Cosmo Pharmaceuticals / Cosmo Technologies: Watch this Company!

7.7.1 MMX Revenues

8 World Markets by Region

8.1 Changing Regional Market Share

8.2 North America: Slower Growth, Market Share in 2024 Compared with 2009

8.3 Europe: Retaining Market Share in the Long Term?

8.3.1 United Kingdom

8.3.2 Germany

8.3.3 Poland: Increasing in Market Relevance

8.4 Africa, Asia, Australasia: Growing Markets

8.4.1 The Incidence and Prevalence of IBD in Asia

8.4.2 Japan

8.4.3 Australia

8.4.4 China

8.4.5 India

8.5 Latin America

9 Strengths, Weaknesses, Opportunities and Threats of the IBD Market

9.1 Strengths

9.1.1 Monoclonal Antibodies: a Threat to Intestinal Anti-Inflammatories?

9.2 Weaknesses

9.2.1 Genotyping: A Dead End?

9.3 Opportunities

9.4 Threats

9.4.1 Cures and/or Vaccines?

9.4.2 Market Saturation

9.4.3 The World Economic Climate - Will this Limit Uptake of New IBD Drugs in a
Nearly-Saturated Market?

10 Interviews with Relevant Key Opinion Leaders

10.1 Interview with Marco Greco, Chairman of the European Federation of Crohn`s
and Ulcerative Colitis Associations (EFCCA).

10.1.1 Public Awareness

10.1.2 Differences Between European Countries

10.1.3 Drug Companies` Involvement in Awareness Campaigns

10.1.4 Unmet Medical Needs

10.2 Interview with Dr. Alan Fraser, Associate Professor of Medicine, University
of Auckland, Director for Clinical Examinations at Auckland Hospital.

10.2.1 Autoimmunity vs. Infection Theories

10.2.2 Monoclonal Antibodies

10.2.3 Genotyping

10.2.4 Remaining Therapeutic Gaps

10.2.5 Future Treatments

10.3 Interview with Professor Thomas Borody, MD, PhD, Director of the Centre for
Digestive Diseases (Sydney), and Executive Director and Chief Medical Officer of
Giaconda Limited

10.3.1 Mycobacterium avium paratuberculosis (MAP) Infection and IBD Aetiology

10.3.2 IBD and HIV/AIDS

10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments

10.3.4 Potential Cure(s)

10.3.5 Remicade and MAP

10.3.6 Genotyping

10.3.7 Crohn`s vs. Colitis

10.3.8 Future Therapies

10.3.9 Potential and Future of Myconda

11 Conclusions

11.1 IBD Market Sales Forcasts

11.2 The Market will be Stimulated by New Delivery Technologies and New Drug
Targets

11.3 Many Drugs and Generics on the Market, but Poor Disease Management Means
High Potential Drug Uptake

11.4 The IBD Market - Will Sales Growth Continue Steadily from 2009 to 2024?

List of Tables

Table 3.1 The Most Common Autoimmune Disorders, by Type

Table 4.1 IBD Drugs by Type, Chemical Name and Brand Name

Table 5.1 World Intestinal Anti-Inflammatories Sales Forecasts, 2009-2024

Table 5.2 Lialda Sales Forecast, 2009-2024

Table 5.3 Asacol Sales Forecast, 2009-2024

Table 5.4 Entocort Sales Forecast, 2009-2024

Table 5.5 Pentasa Sales Forecast, 2009-2024

Table 5.6 Salofalk Sales Forecast, 2009-2024

Table 5.7 Budenofalk Sales Forecast, 2009-2024

Table 5.8 Colazal Sales Forecast, 2009-2024

Table 5.9 Autoimmune-Indicated Monoclonal Antibodies Forecasts, 2009-2024

Table 5.10 Remicade Sales Forecast, 2009-2024

Table 5.11 Humira Sales Forecast, 2009-2024

Table 5.12 Cimzia Sales Forecast, 2009-2024

Table 5.13 Tysabri Sales Forecast, 2009-2024

Table 6.1 Interleukin-targeted Drugs Pipeline, by Phase and Company, 2008

Table 8.1 World Intestinal Anti-Inflammatories Sales Forecasts, 2009-2024

Table 8.2 World Market Sales Forecasts by Region, 2009-2024

Table 8.3 North America Sales Forecast, 2009-2024

Table 8.4 Europe Sales Forecast, 2009-2024

Table 8.5 Africa, Asia, Australasia Sales Forecast, 2009-2024

Table 8.6 Latin America Sales Forecast, 2009-2024

Table 9.1 Strengths and Weaknesses in the IBD Market

Table 9.2 Opportunities and Threats in the IBD Market

List of Figures

Figure 2.1 Direct and Indirect Medical Costs of IBD in 4 Countries

Figure 5.1 World Intestinal Anti-Inflammatories Market Projection, 2009-2024

Figure 5.2 IBD Market Breakdown by Drug Type, 2008

Figure 5.3 Top-Selling IBD Drugs, 2008

Figure 5.4 Sales Forecasts of Top-Selling IBD Drugs, 2009-2024

Figure 5.5 Lialda Sales Forecast, 2009-2024

Figure 5.6 Asacol Sales Forecast, 2009-2024

Figure 5.7 Entocort Sales Forecast, 2009-2024

Figure 5.8 Pentasa Sales Forecast, 2009-2024

Figure 5.9 Salofalk Sales Forecast, 2009-2023

Figure 5.10 Budenofalk Sales Forecast, 2009-2024

Figure 5.11 Colazal Sales Forecast, 2009-2024

Figure 5.12 Autoimmune-indicated Monoclonal Antibodies Forecast

Figure 5.13 Remicade Sales Forecast, 2009-2024

Figure 5.14 Humira Sales Forecast, 2009-2024

Figure 5.15 Cimzia Sales Forecast, 2009-2024

Figure 5.16 Tysabri Sales Forecast, 2009-2024

Figure 7.1 Top IBD Companies, 2008

Figure 8.1 World Intestinal Anti-Inflammatories Sales Forecast, 2009-2024

Figure 8.2 Regional Sales Forecasts, 2009-2024

Figure 8.3 Market Share by World Region, 2014 Projection

Figure 8.4 Market Share by World Region, 2024 Projection

Figure 8.5 North America Sales Forecast, 2009-2024

Figure 8.6 Europe Sales Forecast, 2009-2024

Figure 8.7 Africa, Asia, Australasia Sales Forecast, 2009-2024

Figure 8.8 Latin America Sales Forecast, 2009-2024

Companies Listed

Abbott

Alaven Pharm

Amgen

AstraZeneca

Atlantic Healthcare

Biogen Idec

Biovail

Biovitrum

Bristol-Myers Squibb

Center for Digestive Diseases (Sydney)

Centocor

ChemoCentryx

Committee for Medicinal Products for Human Use (CHMP)

Conaris Research Institute AG

Cosmo Pharmaceuticals, S.p.A.

Cosmo Technologies, Ltd.

Crohn's and Colitis Foundation of America (CCFA)

Dong A

Dr. Falk Pharma

Elan (Ireland)

European Federation of Crohn's and Colitis Associations (EFCCA)

European Medicines Agency (EMEA)

Faes Farma

Ferring

Food and Drug Administration (FDA)

Genmat

Genzyme

Giaconda

Giuliani

GlaxoSmithKline

Isis Pharmaceuticals

Johnson & Johnson

Medarex

Merck

Novartis

Osiris Therapeutics

Pediatric Inflammatory Bowel Disease Center at Cedars-Sinai Medical Center in
Los Angeles

Pfizer

Probiotic Therapy Research Center, Sydney

Procter & Gamble

Prometheus Laboratories

Salix

Santarus

Santen

Schering-Plough

Shire

Stanford University

Synergen

Therakos

University of Washington

Wyeth

ZymoGenetics

To order this report:

Inflammatory Bowel Diseases: World Market Report 2009-2024

http://www.reportlinker.com/p0109865/Inflammatory-Bowel-Diseases-World-Market-Report-2009-2024.html

More market research reports here!

Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

Copyright Business Wire 2009